Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
- PMID: 17435765
- DOI: 10.1038/nsmb1235
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia
Abstract
Proprotein convertase subtilisin kexin type 9 (PCSK9) lowers the abundance of surface low-density lipoprotein (LDL) receptor through an undefined mechanism. The structure of human PCSK9 shows the subtilisin-like catalytic site blocked by the prodomain in a noncovalent complex and inaccessible to exogenous ligands, and that the C-terminal domain has a novel fold. Biosensor studies show that PCSK9 binds the extracellular domain of LDL receptor with K(d) = 170 nM at the neutral pH of plasma, but with a K(d) as low as 1 nM at the acidic pH of endosomes. The D374Y gain-of-function mutant, associated with hypercholesterolemia and early-onset cardiovascular disease, binds the receptor 25 times more tightly than wild-type PCSK9 at neutral pH and remains exclusively in a high-affinity complex at the acidic pH. PCSK9 may diminish LDL receptors by a mechanism that requires direct binding but not necessarily receptor proteolysis.
Similar articles
-
Characterisation of de novo mutations in the C-terminal domain of proprotein convertase subtilisin/kexin type 9.Protein Eng Des Sel. 2015 May;28(5):117-25. doi: 10.1093/protein/gzv008. Epub 2015 Mar 4. Protein Eng Des Sel. 2015. PMID: 25744035
-
Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation.J Biol Chem. 2007 Jul 13;282(28):20502-12. doi: 10.1074/jbc.M701634200. Epub 2007 May 10. J Biol Chem. 2007. PMID: 17493938
-
The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR.Traffic. 2007 Jun;8(6):718-32. doi: 10.1111/j.1600-0854.2007.00562.x. Epub 2007 Apr 25. Traffic. 2007. PMID: 17461796
-
Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.Drug News Perspect. 2008 Jul-Aug;21(6):323-30. doi: 10.1358/dnp.2008.21.6.1246795. Drug News Perspect. 2008. PMID: 18836590 Review.
-
Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.Nutr Metab Cardiovasc Dis. 2011 Nov;21(11):835-43. doi: 10.1016/j.numecd.2011.06.002. Epub 2011 Sep 23. Nutr Metab Cardiovasc Dis. 2011. PMID: 21943799 Review.
Cited by
-
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.J Biol Chem. 2016 Aug 5;291(32):16659-71. doi: 10.1074/jbc.M116.717736. Epub 2016 Jun 8. J Biol Chem. 2016. PMID: 27284008 Free PMC article.
-
The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis.Lipids Health Dis. 2019 Apr 30;18(1):105. doi: 10.1186/s12944-019-1036-1. Lipids Health Dis. 2019. PMID: 31036026 Free PMC article.
-
Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors.J Lipid Res. 2011 Oct;52(10):1787-94. doi: 10.1194/jlr.M018093. Epub 2011 Jul 19. J Lipid Res. 2011. PMID: 21771976 Free PMC article.
-
Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Curr Atheroscler Rep. 2014 Sep;16(9):439. doi: 10.1007/s11883-014-0439-8. Curr Atheroscler Rep. 2014. PMID: 25052769 Review.
-
Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.PLoS One. 2014 Dec 4;9(12):e114469. doi: 10.1371/journal.pone.0114469. eCollection 2014. PLoS One. 2014. PMID: 25474576 Free PMC article.
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous